Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

1.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.1K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

58
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
58
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-NMDA receptor encephalitis outcomes in a population-based cohort.

Journal of neurology·2026
Same author

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Neurology·2026
Same author

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in MS Treatment.

Annals of neurology·2025
Same author

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Neurology·2025
Same author

Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA.

Nature reviews. Neurology·2025

Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K

Multiple sclerosis, rituximab, and COVID-19.

Annette Langer-Gould1, Jessica B Smith2, Bonnie H Li2

  • 1Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, CA, USA.

Annals of Clinical and Translational Neurology
|March 30, 2021
PubMed
Summary

Persons with multiple sclerosis (pwMS) treated with rituximab had higher hospitalization rates for COVID-19 but no increased mortality. Precautions are advised in the 5 months post-infusion.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Related Experiment Videos

Last Updated: Nov 11, 2025

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Area of Science:

  • Immunology
  • Neurology
  • Infectious Diseases

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Rituximab is an immunosuppressive therapy used for treating MS.
  • The impact of rituximab on COVID-19 outcomes in MS patients requires further investigation.

Purpose of the Study:

  • To evaluate the association between rituximab treatment and COVID-19 outcomes in persons with multiple sclerosis (pwMS).
  • To identify predictors of COVID-19 severity in rituximab-treated pwMS.

Main Methods:

  • Retrospective cohort study conducted at Kaiser Permanente Southern California.
  • Inclusion of 1895 rituximab-treated pwMS and a comparison to the general population.
  • Analysis of hospitalization, mortality, and predictors of COVID-19 severity.

Main Results:

  • Rituximab-treated pwMS showed a higher likelihood of COVID-19 hospitalization (33.3%) compared to the general population (5.8%).
  • No significant difference in COVID-19 mortality was observed between rituximab-treated pwMS (0%) and the general population (1.4%).
  • Independent predictors of COVID-19 severity included time since last infusion and rituximab dose (1000 mg vs. lower doses).

Conclusions:

  • Rituximab-treated pwMS require heightened vigilance for COVID-19, particularly within 5 months post-infusion.
  • Consideration of extended dosing intervals and reduced doses may mitigate COVID-19 risks.
  • Further research into optimizing immunosuppressive therapy during the pandemic is warranted.